Vanda Pharmaceuticals Inc. (VNDA) analyst actions
Rating and price-target actions on VNDA in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the VNDA overview →
1 measured VNDA analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists | Press release | -0.34% | +0.55% |
Keep exploring
More VNDA: earnings → · SEC filings → · VNDA overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Bio-Techne Corp (TECH) | 363 | -0.06% | 44% |
| Tenet Healthcare Corporation (THC) | 363 | +0.22% | 60% |
| Rezolute, Inc. - (NV) (RZLT) | 362 | -0.23% | 44% |
| Erytech Pharma S.A. - American Depositary Shares (ERYP) | 360 | 0.00% | 29% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.